Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | LTK | P29376 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168659 | 0.84 | POLB (0.61) | ADORA3PDGFRALIMK1CDK5AURKB | |
| SCHEMBL1857868 | 0.78 | NPC1 (0.54) | ADORA3HSD17B10CLK4KDM4ENPC1 | |
| SCHEMBL3499089 | 0.78 | ALPL (0.57) | ADORA3HSD17B10KDM4ENPC1GAA | |
| SCHEMBL28025294 | 0.78 | POLB (0.48) | ADORA3AURKBPOLBRAB9ALMNA | |
| SCHEMBL17355073 | 0.78 | ALOX15 (0.58) | HSD17B10KDM4ENPC1GAARAB9A | |
| SCHEMBL31324688 | 0.78 | ALPL (0.57) | ADORA3HSD17B10KDM4ENPC1GAA | |
| SCHEMBL18803859 | 0.78 | L3MBTL1 (0.72) | ADORA3HSD17B10CSF1RAURKBKDM4E | |
| SCHEMBL3502511 | 0.78 | IDO1 (0.49) | ADORA3HSD17B10KDM4ENPC1GAA | |
| SCHEMBL2083395 | 0.78 | IDO1 (0.49) | ADORA3HSD17B10KDM4ENPC1GAA | |
| SCHEMBL5261707 | 0.75 | HDAC3 (0.45) | HSD17B10MAP4K4CSF1RFGFR1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969741-B2 | Pyrazolotriazines as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2018-05-15 | — | — | US | disclosed |
| US-9969741-B2 | Pyrazolotriazines as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2018-05-15 | — | — | US | disclosed |
| EP-2957562-B1 | PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2017-12-20 | — | — | EP | disclosed |
| US-20170197966-A1 | PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2017-07-13 | — | — | US | disclosed |
| US-20170197966-A1 | PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2017-07-13 | — | — | US | disclosed |
| EP-2957562-A1 | Pyrazolotriazines as inhibitors of nucleases | Masarykova univerzita (CZ) | 2015-12-23 | — | — | EP | disclosed |
| WO-2015192817-A1 | PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197966-A1 | PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES | DNASE1, TDP1, RNASEH1 | ADORA3 1708/4885HSD17B10 2930/4885MAP4K4 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.